LifeMD secures a $50 million credit facility from Citizens Bank to support growth initiatives and financial flexibility.
Quiver AI Summary
LifeMD, Inc. has announced the closing of a new senior secured revolving credit facility with Citizens Bank, providing the company with up to $50 million in total availability, which includes $30 million in committed availability and an additional accordion option of $20 million. The facility, slated to mature on January 2, 2029, will not incur an upfront fee and offers competitive pricing terms. LifeMD intends to use its existing cash and cash flow for growth initiatives and sees this credit facility as a means to enhance financial flexibility for potential corporate development or shareholder value creation. The company, known for its virtual primary care services and digital healthcare platform, aims to strengthen its operations with the new funding while expressing gratitude for Citizens Bank's support.
Potential Positives
- LifeMD secured a senior secured revolving credit facility of up to $50 million, enhancing its financial flexibility for corporate development and shareholder value initiatives.
- The facility has a maturity date of January 2, 2029, providing a long-term source of capital for growth.
- The credit facility has no upfront fees, making it a cost-effective option for the company.
- LifeMD is currently in a strong cash position, as no balance has been drawn on the facility at closing, indicating financial stability.
Potential Negatives
- The announcement of a revolving credit facility may indicate that the company is seeking to bolster its liquidity, which could signal potential financial concerns or uncertainty about future cash flows despite current cash on hand.
- The reliance on a credit facility for financial flexibility may raise questions among investors regarding the sustainability of the company's growth and operational strategies without additional debt.
- The forward-looking statements contained in the release carry inherent risks and uncertainties, which could affect investor confidence and lead to volatility in the company's stock performance.
FAQ
What is LifeMD, Inc.'s recent financial announcement?
LifeMD announced a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability.
Who is providing the credit facility to LifeMD?
The credit facility is being provided by Citizens Bank, N.A., a leading national bank.
What will LifeMD use the funds from the credit facility for?
The funds will support LifeMD's organic growth initiatives and potential corporate development or shareholder value creation initiatives.
What are the terms of the credit facility's interest rates?
Loans under the facility bear interest based on Term SOFR or the Alternate Base Rate, with spreads ranging from 50 to 225 basis points.
How does LifeMD ensure quality healthcare services?
LifeMD utilizes a proprietary digital care platform, a medical group across all 50 states, and an affiliated pharmacy to provide high-quality care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LFMD Insider Trading Activity
$LFMD insiders have traded $LFMD stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $LFMD stock by insiders over the last 6 months:
- NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760
- JESSICA FRIEDEMAN (Chief Marketing Officer) sold 15,000 shares for an estimated $54,157
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LFMD Revenue
$LFMD had revenues of $60.2M in Q3 2025. This is an increase of 12.95% from the same period in the prior year.
You can track LFMD financials on Quiver Quantitative's LFMD stock page.
$LFMD Hedge Fund Activity
We have seen 57 institutional investors add shares of $LFMD stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. removed 925,685 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,285,401
- D. E. SHAW & CO., INC. removed 775,284 shares (-63.6%) from their portfolio in Q3 2025, for an estimated $5,264,178
- CITADEL ADVISORS LLC added 657,824 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,466,624
- MORGAN STANLEY removed 617,525 shares (-38.8%) from their portfolio in Q3 2025, for an estimated $4,192,994
- RENAISSANCE TECHNOLOGIES LLC added 547,625 shares (+50.4%) to their portfolio in Q3 2025, for an estimated $3,718,373
- JUMP FINANCIAL, LLC removed 467,652 shares (-90.8%) from their portfolio in Q3 2025, for an estimated $3,175,357
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 434,937 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,953,222
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LFMD Analyst Ratings
Wall Street analysts have issued reports on $LFMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/19/2025
- Keybanc issued a "Overweight" rating on 11/19/2025
- Lake Street issued a "Buy" rating on 11/18/2025
- BTIG issued a "Buy" rating on 11/18/2025
- B. Riley Securities issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for $LFMD, check out Quiver Quantitative's $LFMD forecast page.
$LFMD Price Targets
Multiple analysts have issued price targets for $LFMD recently. We have seen 8 analysts offer price targets for $LFMD in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Steve Dechert from Keybanc set a target price of $8.0 on 11/19/2025
- Steven Valiquette from Mizuho set a target price of $6.0 on 11/19/2025
- Yi Chen from HC Wainwright & Co. set a target price of $9.0 on 11/19/2025
- Brooks O'Neil from Lake Street set a target price of $8.0 on 11/18/2025
- David Larsen from BTIG set a target price of $10.0 on 11/18/2025
- William Woods from B. Riley Securities set a target price of $10.0 on 11/18/2025
Full Release
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was drawn on the RCF as the Company believes its cash on hand and expected cash flow are sufficient to fund its organic growth initiatives.
“We are very pleased to close this revolving credit facility with Citizens, a leading national bank. The availability of the additional capital is competitively priced with no upfront fee and provides significant financial flexibility to support potential corporate development and/or shareholder value creation initiatives. We appreciate the support and confidence of Citizens in providing this facility and believe the RCF further underscores the strength and outlook of our business,” said Marc Benathen, Chief Financial Officer of LifeMD.
Based on a pricing grid tied to Company leverage, loans under the facility bear interest based on either (x) Term SOFR plus an applicable spread ranging between 150 basis points and 225 basis points or (y) the Alternate Base Rate plus an applicable spread ranging between 50 basis points and 125 basis points. Fees assessed on the committed unused portion of the facility range from 0.225% to 0.30%, depending upon leverage. The RCF contains no upfront fee to LifeMD.
About LifeMD, Inc.
LifeMD ® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com .
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
[email protected]
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
[email protected]